Headquartered in Santa Monica, CA Fiscal year ends December NASDAQ: GDRX goodrx.com
GoodRx is a U.S.-based platform for medication savings, connecting consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail pharmacies. The company operates three primary revenue streams: prescription transactions (offering savings codes for discounted medication pricing at retail pharmacies), subscription offerings (including GoodRx Gold, condition-specific programs such as weight loss, RxSmartSaver+ powered by GoodRx, and GoodRx Companion), and Pharma Direct (facilitating manufacturer-sponsored pricing programs and GLP-1 access programs through consumer direct pricing). GoodRx serves nearly 25 million consumers and over one million healthcare professionals annually. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications. The company is publicly traded on Nasdaq under the ticker GDRX. Updated
You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans. The default move for decades has been to pick one and forget it.…
Analysts on average recommend buying these nine cheap stocks in a variety of sectors. Their consensus price targets suggest double-digit gains in the coming year.
Friday's top analyst upgrades and downgrades included AppLovin, Crown Castle, GoodRx, Global Payments, Monster Beverage, Penn Entertainment, Plug Power, Roblox, Southern Company and Wynn Resorts.
Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo, Tencent Music Entertainment and more.
Thursday's top analyst upgrades and downgrades included Affirm, Coinbase Global, Dominion Energy, GoodRx, Kroger, Nasdaq, Plug Power, PubMatic, Tyson Foods and Walt Disney.
Monday's top analyst upgrades and downgrades included Altice USA, Arista Networks, Block, Cardinal Health, ConocoPhillips, Datadog, GoodRx, Monster Beverage, PepsiCo, Spirit AeroSystems, Twilio and WeWork.
Wednesday's additional top analyst upgrades and downgrades were on AstraZeneca, Bilibili, Electronic Arts, GoodRx, NetEase, Netflix, Pinterest, U.S. Foods and more.
Monday’s top analyst upgrades and downgrades included Archer Daniels Midland, Crowdstrike, GoodRx, Illumina, Oracle, Payoneer Global, Palo Alto Networks, Playa Hotels, Rivian Automotive, Salesforce, Teladoc, Toast and Warby Parker.
Wednesday’s top analyst upgrades and downgrades included Amgen, Bed Bath & Beyond, Carlyle, Coinbase Global, Enovix, GoodRx, Healthcare Realty Trust, Micron Technology, NRG Energy, Nutrien, Nvidia, Roku, Take-Two Interactive Software and Tellurian.
Monday's top analyst upgrades and downgrades included Docusign, Electronic Arts, Enterprise Products Partners, GoodRx, Netflix, Spirit Airlines, Take-Two Interactive Software, Target, Tesla and Vonage.
Tuesday's top analyst upgrades and downgrades included Best Buy, Cigna, Exxon Mobil, Futu, GoodRx, Lululemon Athletica, Merck, Monster Beverage, MP Materials, Nike, Visa and Walmart.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Wednesday’s additional top analyst upgrades and downgrades were on Danaher, eBay, GoodRx, Infosys, Valero Energy, Xylem and more.
Wednesday's top analyst upgrades and downgrades included Affirm, Bausch + Lomb, Electronic Arts, EOG Resources, Foot Locker, Ford, GoodRx, Goodyear Tire, Healthcare Trust of America, Simon Property, Tesla and Unity Software.
Tuesday’s additional top analyst upgrades and downgrades were on Affirm, Edison International, GoodRx, LivePerson, Palantir Technologies, Progressive, Upstart and more.
GoodRx is a U.S.-based platform for medication savings, connecting consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail pharmacies.
24/7 Wall St.'s 12-month price target for GDRX is $3.95, rated Buy. The Wall Street consensus target is $3.95. GDRX price prediction →
